Clinical trials
Primary Biliary Cirrhosis clinical trials
Below are recruiting primary biliary cirrhosis clinical trials, each written for real people, not researchers. We’re tracking 19 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06051617RecruitingPhase 3
Testing seladelpar for PBC with compensated cirrhosis
This study tests an experimental oral drug called seladelpar for people with PBC who also have cirrhosis that is well-controlled. The goal is to see if it helps improve liver health and manage symptoms without causing serious side effects.
Birmingham, AlabamaAges 18 years+ - NCT06723275Recruiting
A study on liver transplant for different liver diseases
This trial is testing a new way to see how well patients do after a liver transplant. It includes people with severe cirrhosis, other end-stage liver diseases, or liver cancer.
Ghent, BelgiumAges 18–70 - NCT06675604Recruiting
Liver transplant data collection study
This study collects data from adults listed for liver transplants due to severe liver disease or liver cancer. It aims to improve transplant care by learning from real-world patient information.
ViennaAges 18–70 - NCT03445585Recruiting
Biobank study for primary sclerosing and primary biliary cholangitis
This study collects and stores samples from people with PSC (primary sclerosing cholangitis), PBC (primary biliary cholangitis), and some related liver conditions. Researchers use these samples to better understand these diseases and support future research.
Rochester, MinnesotaAges 18–85 - NCT04514965Recruiting
Bezafibrate for primary biliary cholangitis patients
This trial studies whether bezafibrate, a medication, can help people with primary biliary cholangitis (PBC). You may be considered if your care team is already considering bezafibrate and you meet safety requirements.
Aarhus N, Central JutlandAges 18–99 - NCT05749822RecruitingPhase 2/Phase 3
Fenofibrate for primary biliary cholangitis with stable cirrhosis
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
Beijing, Beijing MunicipalityAges 18–75 - NCT05050136RecruitingPhase 2
Volixibat trial for itch from primary biliary cholangitis
This Phase 2 study tests whether volixibat can safely reduce itching caused by primary biliary cholangitis (PBC). If you have PBC-related itch that persists, this trial may help you find a new treatment option.
Coronado, CaliforniaAges 18 years+ - NCT07161245Recruiting
Fatigue relief study for primary biliary cholangitis
This trial tests a program of exercise, nutrition, and education to help reduce fatigue in people with primary biliary cholangitis. It aims to see if this program can improve energy and quality of life.
Barcelona, BarcelonaAges 18–80 - NCT06016842RecruitingPhase 3
Long-term study of elafibranor for primary biliary cholangitis
This trial tests a drug called elafibranor for people with primary biliary cholangitis (PBC), a liver disease. It aims to see if the drug is safe and works well over a long time.
Tucson, ArizonaAges 18 years+ - NCT06519162Recruiting
Liver-gut link study for liver disease patients and their families
This study looks at how gut bacteria differ in people with specific liver diseases and their household contacts. It may help researchers understand the connection between the liver and gut.
Daejeon, Jung-guAges 19 years+ - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT02931513Recruiting
Blood marker test in newly diagnosed PBC patients
This study looks at how a specific blood marker (sCD163) changes in people newly diagnosed with primary biliary cholangitis (PBC). It’s mainly meant to see whether this marker could help predict treatment response, especially before starting UDCA.
Aarhus C, Central JutlandAges 18 years+ - NCT07598669Recruiting
Austrian Primary Biliary Cholangitis Registry Study
This is a registry study that collects health information from people with primary biliary cholangitis (PBC), a rare liver disease where the immune system damages bile ducts. By joining, you help researchers better understand PBC and improve care for patients with this condition.
Klagenfurt, CarinthiaAges 18 years+ - NCT07304843RecruitingPhase 1/Phase 2
Testing golexanolone for fatigue and brain fog in PBC
This study tests an experimental drug called golexanolone to see if it can help with fatigue and thinking problems in people with primary biliary cholangitis (PBC). It involves taking two different doses of the drug and checking how you feel and think over time.
DüsseldorfAges 18 years+ - NCT07216235RecruitingPhase 3
Long-term study of saroglitazar for PBC with cirrhosis
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Marietta, GeorgiaAges 18 years+ - NCT01212250Recruiting
Carvedilol to prevent esophagus bleeding in cirrhosis
This trial tests whether carvedilol can prevent the first development of swollen veins (varices) in the esophagus in people with cirrhosis who do not have them yet. It may help lower the risk of future bleeding from those veins.
New Delhi, National Capital Territory of DelhiAges 18–75 - NCT04650243RecruitingPhase 4
Testing whether lowering UDCA helps people with PBC
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
BeijingAges 18 years+ - NCT07282353RecruitingPhase 3
Study of CS0159 for primary biliary cholangitis with poor UDCA response
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
Hefei, AnhuiAges 18–75 - NCT03569826Recruiting
Study for primary biliary cholangitis and autoimmune hepatitis
This study is for people diagnosed with primary biliary cholangitis or autoimmune hepatitis. It aims to learn more about these autoimmune liver conditions and may help guide better care in the future.
Calgary, AlbertaAges 18 years+
Hear when a new Primary Biliary Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary biliary cirrhosis?
- Yes. Clin2 currently lists 19 recruiting primary biliary cirrhosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary biliary cirrhosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary biliary cirrhosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.